Today

Agents

Chat

Arena

Discover

More

App

Vaxcyte Q2 Operating Expenses USD 302.777 Million - PCVX News | Rallies

Vaxcyte Q2 Operating Expenses USD 302.777 Million

PCVX•2026-08-05

Q2 net income and operating expenses

Aug. 05 (Reuters) - Vaxcyte Q2 net income was USD -284.302 million vs. IBES estimate of USD -298.3 million.

Vaxcyte Q2 operating expenses were USD 302.777 million.

Related News

PhenixFIN FY26 Q3 net investment income totals $2.1 million; total investment income reaches $6.5 million

PFX•2026-08-05

Corpay cites favorable macro conditions, corporate payments strength behind Q2 2026 results

CPAY•2026-08-05

Arcus Biosciences Q2 revenue falls sharply on lower license income

RCUS•2026-08-05

PacBio names COO Mark Van Oene CEO, replacing Christian Henry

PACB•2026-08-05

Ibotta CTO Luke Roy Swanson sells USD 290,536 in Class A shares

IBTA•2026-08-05